Proportion of participants who have a four-fold increase in the dose of peanut protein needed to induce positive challenge (with final threshold dose >1000 mg) at the 6 month oral food challenge 6 months [clinicaltrials_resource:2d8968895b768476b5ec9f5943f6bed3]
omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Proportion of participants who have a four-fold increase in the dose of peanut protein needed to induce positive challenge (with final threshold dose >1000 mg) at the 6 month oral food challenge 6 months [clinicaltrials_resource:2d8968895b768476b5ec9f5943f6bed3]
omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
Bio2RDF identifier
2d8968895b768476b5ec9f5943f6bed3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2d8968895b768476b5ec9f5943f6bed3
measure [clinicaltrials_vocabulary:measure]
Proportion of participants who ...... he 6 month oral food challenge
time frame [clinicaltrials_vocabulary:time-frame]
description
omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
identifier
clinicaltrials_resource:2d8968895b768476b5ec9f5943f6bed3
title
Proportion of participants who ...... h oral food challenge 6 months
@en
type
label
Proportion of participants who ...... 968895b768476b5ec9f5943f6bed3]
@en